Exploring Novel Therapeutic Options: Inhibitors for Neglected Diseases

Xavier Nguyen^*
*Correspondence: Xavier Nguyen, Department of Health Science, Florida State University, Moscow, ID 83843, United States, Email:

Introduction

Diseases, prevalent in low-income regions and often disregarded by pharmaceutical companies, pose a significant global health challenge. Conventional drug discovery efforts tend to neglect these diseases due to financial constraints and a lack of market potential. Nevertheless, the rise of covalent inhibitors provides a promising pathway for the creation of innovative therapeutics. This article delves into the potential of covalent inhibitors in combating neglected diseases, elucidating their mechanisms of action, ongoing research endeavors, and future possibilities.

Description

Covalent inhibitors form a unique category of therapeutics that establish irreversible bonds with their target proteins, resulting in prolonged and potent inhibition. Unlike reversible inhibitors, which rely on non-covalent interactions like hydrogen bonding or van der Waals forces, covalent inhibitors exploit nucleophilic residues within the target protein to establish stable covalent bonds. This mechanism offers several advantages, including heightened selectivity, extended action duration, and reduced susceptibility to resistance mechanisms. The mechanism of action of covalent inhibitors involves three primary steps: reversible binding, covalent bond formation, and irreversible inhibition. Initially, the inhibitor binds reversibly to the active site of the target protein, positioning its reactive group near a nucleophilic residue, often a cysteine or lysine residue. Subsequent nucleophilic attack by the target residue results in covalent bond formation, effectively immobilizing the inhibitor. This irreversible modification disrupts the function of the target protein, leading to inhibition of the biological process it governs. Neglected diseases encompass a wide range of infectious and non-infectious ailments, including malaria, tuberculosis, Chagas disease, and leishmaniasis, among others [1].

Despite their significant impact on global health, treatment options are limited, often plagued by issues such as drug resistance and toxicity. Covalent inhibitors offer a promising strategy to tackle these challenges by targeting vital proteins and pathways within the causative agents of neglected diseases. A notable example is the application of covalent inhibitors against Plasmodium falciparum, the malaria parasite. By targeting crucial enzymes involved in parasite survival, such as dihydrofolate reductase or cysteine proteases, covalent inhibitors have demonstrated potent antimalarial effects in preclinical studies. Furthermore, their irreversible mode of action diminishes the likelihood of resistance development, a common concern with conventional antimalarial medications. Likewise, covalent inhibitors have exhibited potential in addressing bacterial infections, notably those instigated by multidrug-resistant strains of Mycobacterium tuberculosis. By targeting vital enzymes involved in bacterial cell wall synthesis or metabolism, covalent inhibitors present a fresh avenue to combat antibiotic resistance and enhance treatment outcomes in tuberculosis patients [2].

While the promise of covalent inhibitors in neglected diseases is evident, numerous challenges must be tackled to transform this potential into clinical reality. Primarily, identifying suitable target proteins and designing selective covalent inhibitors present significant hurdles, particularly for pathogens with intricate biology or limited structural insights. Progress in computational modeling, high-throughput screening, and chemical synthesis is imperative to surmount these obstacles and expedite inhibitor discovery. Additionally, concerns regarding off-target effects and toxicity remain paramount, underscoring the necessity of thorough preclinical assessment and safety profiling. Moreover, the accessibility and affordability of covalent inhibitors for patients in resource-constrained settings must be addressed to ensure fair access to these life-saving treatments. Implementing tailored vector control measures is crucial in combating neglected diseases. For instance, employing insecticide-treated bed nets or indoor residual spraying targets malaria, transmitted by Anopheles mosquitoes. Developing genetically modified mosquitoes or vectors incapable of disease transmission is another avenue [3].

This includes releasing sterile insects or introducing genes that disrupt pathogen transmission. Gene-drive technologies can spread genetic modifications making vectors resistant to transmitted pathogens, potentially halting disease spread. Transmission-blocking vaccines targeting pathogens within vectors interrupt disease cycles, notably explored in malaria. Immune-based interventions like introducing symbiotic bacteria into vector populations, such as Wolbachia-infected mosquitoes for dengue control, show promise. Community engagement through education and participation empowers affected communities in vector control decisions. Despite challenges, ongoing research and collaborations across academia, industry, and nonprofits offer hope in advancing covalent inhibitor-based therapeutics for neglected diseases. Leveraging innovative technologies and interdisciplinary approaches, researchers can overcome barriers, developing novel treatments meeting the medical needs of vulnerable populations globally [4-6].

Conclusion

Covalent inhibitors offer a promising avenue for neglected disease treatment, providing potent and selective inhibition of crucial proteins in disease-causing pathogens. Their irreversible binding mechanisms hold potential for overcoming drug resistance and enhancing treatment efficacy, particularly in resource-limited settings. Yet, considerable challenges persist, such as identifying suitable targets, designing effective inhibitors, and ensuring safety. Through collaborative endeavors and ongoing investment in research and development, covalent inhibitors could become invaluable tools in combating neglected diseases. Ultimately, their integration into therapeutic strategies has the potential to significantly ameliorate global health outcomes and alleviate the burden of infectious and non-infectious diseases in marginalized communities.

Acknowledgement

None.

Conflict of Interest

There are no conflicts of interest by author.

References

1. Borea, Pier Andrea, Stefania Gessi, Stefania Merighi and Fabrizio Vincenzi, et al. "Pharmacology of adenosine receptors: The state of the art." Physiol Rev 98 (2018): 1591-1625.

Google Scholar, Crossref, Indexed at

2. Kulkarni, Shashank, Klaus Urbahns and Thomas Spangenberg. "Targeted covalent inhibitors for the treatment of malaria?." ACS Infect Dis 6 (2020): 2815-2817.

Google Scholar, Crossref, Indexed at

3. Cullia, Gregorio, Stefano Bruno, Silvia Parapini and Marilena Margiotta, et al. "Covalent inhibitors of Plasmodium falciparum glyceraldehyde 3-phosphate dehydrogenase with antimalarial activity in vitro." ACS Med Chem Lett 10 (2019): 590-595.

Google Scholar, Crossref, Indexed at

4. Bruns, Robert F. "Adenosine receptor activation by adenine nucleotides requires conversion of the nucleotides to adenosine." Arch Pharmacol 315 (1980): 5-13.

Google Scholar, Crossref, Indexed at

5. Kerr, Iain D., Ji H. Lee, Christopher J. Farady and Rachael Marion, et al. "Vinyl sulfones as antiparasitic agents and a structural basis for drug design." J Biol Chem 284 (2009): 25697-25703.

Google Scholar, Crossref, Indexed at

6. Ettari, Roberta, Santo Previti, Santina Maiorana and Giorgio Amendola, et al. "Optimization strategy of novel peptide-based Michael acceptors for the treatment of Human African Trypanosomiasis." J Med Chem 62 (2019): 10617-10629.

Google Scholar, Crossref, Indexed at